AG 1295

Drug Profile

AG 1295

Latest Information Update: 19 Sep 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Friedrich Schiller University
  • Developer Friedrich Schiller University; Nonindustrial source
  • Class Antineoplastics; Tyrphostins
  • Mechanism of Action Platelet-derived growth factor receptor antagonists; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Cancer; Reperfusion injury

Most Recent Events

  • 19 Sep 2001 Discontinued-Preclinical for Acute myeloid leukaemia in USA (Unknown route)
  • 19 Sep 2001 Discontinued-Preclinical for Cancer in Germany (Unknown route)
  • 19 Sep 2001 Discontinued-Preclinical for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top